Aug. 12 at 12:39 PM
$XLO This Q2 update highlights several meaningful developments.
- FDA clearance of the XTX501 IND
-
$136M in cash on hand
- Cash runway extended into Q1 2028
- Up to
$75M in potential proceeds from the Gilead decision
- Up to
$31M in near-term milestones and fees from AbbVie
- Two additional TCE INDs targeted for H2 2027
At approximately
$9 per share, the market continues to assign limited value to the pipeline beyond the company’s cash position.
With XTX501 now advancing into the clinic, alongside external validation from Gilead and AbbVie, the balance sheet materially reduces near-term dilution risk.
Still holding!
